The FDA has approved brepocitinib (Lisraya), marking the first oral therapy designed specifically for dermatomyositis, a rare autoimmune disease that attacks muscles and skin. For patients who have relied on high-dose steroids for years, this approval represents a meaningful shift toward a targeted treatment option that addresses the underlying immune dysfunction driving the disease.

What Is Dermatomyositis and Why Does It Matter?

Dermatomyositis is a rare autoimmune condition in which the immune system mistakenly attacks muscle and skin tissue, causing chronic inflammation, progressive muscle weakness, and distinctive skin rashes that are often painful and disfiguring. Patients have historically depended on long-term, high-dose corticosteroids to manage symptoms, which come with significant side effects including weight gain, bone loss, and increased infection risk. The lack of targeted therapies meant doctors often borrowed treatments from other autoimmune diseases, leaving patients with limited options.

Brepocitinib works differently. It is a selective tyrosine kinase 2-Janus kinase 1 (TYK2-JAK1) inhibitor, meaning it blocks specific immune signaling pathways that drive inflammation in dermatomyositis. By dampening these pathways, the drug reduces the immune attack on muscle and skin tissue, allowing patients to heal while reducing their dependence on steroids.

How Effective Was Brepocitinib in Clinical Trials?

The approval was based on results from the VALOR trial, a phase 3 study that enrolled 241 adults with dermatomyositis whose disease had not responded adequately to previous treatments. Participants were randomly assigned to receive brepocitinib at 30 milligrams daily, 15 milligrams daily, or placebo for 52 weeks, while continuing their standard therapies and gradually tapering their steroid doses.

The results showed a clear benefit for the higher dose. At week 52, patients on the 30-milligram dose achieved a mean Total Improvement Score (a validated measure of muscle and skin disease activity) of 46.5 out of 100, compared to 31.2 for placebo. This represents a significant difference of 15.3 points, with over 95% certainty that the difference was real and not due to chance. The 15-milligram dose did not separate meaningfully from placebo.

Beyond the primary measure, brepocitinib 30 milligrams showed superiority across all nine key secondary endpoints, including skin disease activity, systemic steroid tapering, and functional disability. Improvements appeared as early as week 4, and patients on the higher dose were more likely to successfully reduce their corticosteroid use, a critical goal for long-term health.

What Are the Key Takeaways for Patients and Providers?

• Steroid Reduction: Patients on brepocitinib 30 milligrams were significantly more likely to taper off or reduce their daily corticosteroid doses, reducing exposure to long-term steroid side effects.
• Rapid Onset: Clinical improvements in muscle strength and skin disease were observed as early as week 4 of treatment, offering patients faster relief than some alternative approaches.
• Comprehensive Benefit: The drug improved not only muscle weakness and skin rashes but also functional disability, meaning patients experienced real-world improvements in daily activities and quality of life.

What Safety Concerns Should Patients Know About?

Like other JAK inhibitors, brepocitinib carries a boxed warning, the FDA's most serious safety alert. The most common side effects in the trial included upper respiratory tract infections, headache, fatigue, urinary tract infections, and nausea. Serious infections occurred more frequently in the brepocitinib 30-milligram group (10% of patients) compared to placebo (1%), though no deaths occurred during the trial.

The boxed warning also highlights risks for increased all-cause mortality, malignancies, major adverse cardiovascular events, and blood clots. These are class-level warnings shared across JAK inhibitors, reflecting the drug's mechanism of action on immune signaling. Pharmacists and physicians will need to screen patients carefully for infection risk, cardiovascular disease, and malignancy history before prescribing, and counsel patients on recognizing signs of infection or clotting.

Discontinuation due to adverse reactions occurred in 6% of patients on brepocitinib 30 milligrams versus 11% on placebo, suggesting the drug was generally well-tolerated relative to the comparison group.

What Does This Approval Mean for the Dermatomyositis Community?

For a patient population that has long lacked targeted options, brepocitinib represents a meaningful advance. The FDA granted the drug both Orphan Drug and Priority Review designations, recognizing the unmet medical need in this rare disease. The approval gives patients and their doctors a once-daily oral option that directly addresses the immune dysfunction underlying dermatomyositis, rather than relying solely on broad immunosuppression with steroids.

The drug's ability to enable steroid tapering is particularly significant. Long-term corticosteroid use carries cumulative risks including osteoporosis, infections, metabolic complications, and mood changes. By offering a pathway to reduce steroid dependence while maintaining or improving disease control, brepocitinib may improve long-term health outcomes and quality of life for patients managing this challenging rare disease.